FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Rybak

Research Profile

Procedures

Chemicals & Drugs

Living Beings

Disorders

Physiology

Concepts & Ideas

Biological Models

Co-author Network

Publications

TOP 3
Brian J Werth; Molly E Steed; Glenn W Kaatz; Michael J Rybak
Evaluation of Ceftaroline Activity against Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate Methicillin-Resistant S. aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model: Exploring the "Seesaw Effect".
Kyle P Murray; Jing J Zhao; Susan L Davis; Keith Steven Kaye; Ravina Kullar; Paul Lephart; Michael J Rybak
Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study.
B J Werth; G Sakoulas; Céline Vidaillac; K P Murray; K L Newton; P Nonejuie; Joe Pogliano; Michael J Rybak
Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Rybak (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Brian J Werth; Molly E Steed; Glenn W Kaatz; Michael J Rybak
Evaluation of Ceftaroline Activity against Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate Methicillin-Resistant S. aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model: Exploring the "Seesaw Effect".
Antimicrobial agents and chemotherapy 2013;57(6):2664-8.
2013: Kyle P Murray; Jing J Zhao; Susan L Davis; Keith Steven Kaye; Ravina Kullar; Paul Lephart; Michael J Rybak
Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013;56(11):1562-9.
2013: B J Werth; G Sakoulas; Céline Vidaillac; K P Murray; K L Newton; P Nonejuie; Joe Pogliano; Michael J Rybak
Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.
Antimicrobial agents and chemotherapy 2013;57(5):2376-9.
2013: Ravina Kullar; Donald P Levine; Jason M Pogue; Susan Leroque Davis; Keith Steven Kaye; Michael J Rybak
Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Pharmacotherapy 2013;33(1):3-10.
2013: Kayoko Hayakawa; Melwin Joseph; Hari Kakarlapudi; Naveen Kannekanti; Deepika Reddy Abbadi; Khaled Alshabani; Sarika Bai; Pradeep Bathina; Sowmya Chidurala; Deepti Chowdary; Manoj Das; Sreelatha Diviti; Rajiv Doddamani; Aditya Govindavarjhulla; Harish Guddati; Raviteja Reddy Guddeti; Uma Mahesh Gudur; Paul R Lephart; Sharan Lohithaswa; Ashwini Mallad; Dror Marchaim; Emily T Martin; Venkat Ram Rakesh Mundra; Mohan Palla; Jason M Pogue; Rohan Policherla; Harish Pulluru; Michael J Rybak; Shiva Prasad Shashidharan; Krishna Sukayogula; Praveen Vemuri; Keith Steven Kaye
Epidemiology of vancomycin-resistant Enterococcus faecalis: a case-case-control study.
Antimicrobial agents and chemotherapy 2013;57(1):49-55.
2013: Brian J Werth; Joseph Pogliano; Warren E Rose; George Sakoulas; Ryan Tewhey; Michael J Rybak
Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
Antimicrobial agents and chemotherapy 2013;57(1):66-73.
2012: Michelle L Campbell; Neelu Chugh; Kayoko Hayakawa; Pradeep Bathina; Suchitha Bheemreddy; Kimberley Ku; Paul R Lephart; Dror Marchaim; Emily T Martin; Judy Moshos; Jason M Pogue; Harish Pulluru; Michael J Rybak; Bharath Sunkara; Melanie N Wilson; Keith Steven Kaye
Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
The Annals of pharmacotherapy 2012;46(12):1587-97.
2012: Kayoko Hayakawa; Kevin Ho; Kavyashri Kodlipet Jagadeesh; Sarah Bommarito; Aaisha Chaudhry; Mohamad Farhat; Paul R Lephart; Dror Marchaim; Emily T Martin; Judy A Moshos; Rida Mroue; Priyanka Nanjireddy; Tarek Obeid; Shakila Parveen; Jason M Pogue; Michael J Rybak; Manit Singla; Bharath Sunkara; Gayathri Vadlamudi; Keith Steven Kaye
Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: a case-case-control study.
American journal of infection control 2012;40(10):e261-3.
2012: Theresa Judge; Srinivasa Kamatam; Keith Steven Kaye; Vijaykumar Khammam; Paul R Lephart; Dror Marchaim; Emily T Martin; Priyanka Nanjireddy; Shakila Parveen; Jason M Pogue; Sagar Mallikethi Lepakshi Reddy; Michael J Rybak; Namita Tiwari; Rajachendra Shekher Tumma; Adnan Yousuf; Suchitha Bheemreddy; Caitlin Biedron; Indu K Chalana; Vicki Collins; Kevin Ho; Kayoko Hayakawa
Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2012;33(12):1250-4.
2012: Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2012;56(11):5709-14.
2012: Lisa M Avery; Muhammad Hasan; Molly E Steed; Ashley E Woodruff; Michael J Rybak
Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole.
Antimicrobial agents and chemotherapy 2012;56(11):5990-3.
2012: D T Levy; V Muggia; Philip Gialanella; Y Guo; Lawrence Hanau; Michael J Rybak; M E Steed; B Ostrowsky
Successful treatment of a left ventricular assist device infection with daptomycin non-susceptible methicillin-resistant Staphylococcus aureus: case report and review of the literature.
Transplant infectious disease : an official journal of the Transplantation Society 2012;14(5):E89-96.
2012: Debra A Goff; Michael J Rybak
Introduction to the special issue on antimicrobial stewardship.
Pharmacotherapy 2012;32(8):663-4.
2012: Anthony M Casapao; Donald P Levine; Molly E Steed; Michael J Rybak
Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Expert opinion on pharmacotherapy 2012;13(8):1177-86.
2012: Ashley D Hall; Barbara E Murray; Cesar A Arias; Molly E Steed; Michael J Rybak
Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2012;56(6):3174-80.
2012: Mahender B Dewal; David Oupický; Michael J Rybak; Celine Vidaillac; Amit S Wani; Steven M Firestine
Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents.
European journal of medicinal chemistry 2012;51():145-53.
2012: Kayoko Hayakawa; Srinivasa Kamatam; Pradeep Bathina; Suchitha Bheemreddy; Indu K Chalana; Asma Hasan; Harikrishna Kotra; Kimberly Ku; Sarwan Kumar; Dae-Won Lee; Paul R Lephart; Dror Marchaim; Emily T Martin; Priyanka Nanjireddy; Satyam Patel; Jason M Pogue; Harish Pulluru; Michael J Rybak; Puja Sheth; Bharath Sunkara; Jessie Swan; Namita Tiwari; Amit Vahia; Victoria Yee; Adnan Yousuf; Keith Steven Kaye
Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia.
Antimicrobial agents and chemotherapy 2012;56(5):2452-8.
2012: Molly E Steed; Céline Vidaillac; Patricia Winterfield; Donald Biek; Michael J Rybak
Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.
Antimicrobial agents and chemotherapy 2012;56(5):2691-5.
2012: Jorge Parra Ruiz; Céline Vidaillac; Michael J Rybak
Macrolides and staphylococcal biofilms.
Revista española de quimioterapia : publicación oficial de la Sociedad Española de Quimioterapia 2012;25(1):10-6.
2012: Ravina Kullar; Susan Leroque Davis; Keith Steven Kaye; Thomas N Taylor; Michael J Rybak
Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.
Pharmacotherapy 2012;32(3):195-201.
2012: Molly E Steed; Céline Vidaillac; Michael J Rybak
Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Antimicrobial agents and chemotherapy 2012;56(2):955-9.
2011: Céline Vidaillac; Jorge Parra Ruiz; Michael J Rybak
In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
Diagnostic microbiology and infectious disease 2011;71(4):470-3.
2011: Diixa Patel; Michael J Rybak; Susan M Seo; Molly E Steed; Céline Vidaillac; Mashkur Husain; Glenn W Kaatz
Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus.
International journal of antimicrobial agents 2011;38(5):442-6.
2011: Molly E Steed; Céline Vidaillac; Patricia Winterfield; Glenn W Kaatz; Warren E Rose; Michael J Rybak
Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.
Antimicrobial agents and chemotherapy 2011;55(10):4748-54.
2011: Céline Vidaillac; Patricia Winterfield; Jorge Parra Ruiz; Michael J Rybak
In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
International journal of antimicrobial agents 2011;38(4):301-6.
2011: Kayoko Hayakawa; Teena Chopra; Sorabh Dhar; Asma Hasan; Harikrishna Kotra; Paul Lephart; Dror Marchaim; Adedayo M Osunlana; Jason M Pogue; Michael J Rybak; Hossein Salimnia; Maryann Shango; Bharath Sunkara; Celine Vidaillac; Yashwanth Yerramalla; Keith Steven Kaye
Growing prevalence of vancomycin-resistant Enterococcus faecalis in the region with the highest prevalence of vancomycin-resistant Staphylococcus aureus.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2011;32(9):922-4.
2011: Molly Steed; Céline Vidaillac; Michael J Rybak
Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
Antimicrobial agents and chemotherapy 2011;55(7):3522-6.
2011: Ravina Kullar; Dennis Parker; Judy N Chin; William M Coplin; David J Edwards; Michael J Rybak
Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.
Antimicrobial agents and chemotherapy 2011;55(7):3505-9.
2011: Ravina Kullar; Donald P Levine; Sara E Cosgrove; Christopher W Crank; Susan Leroque Davis; George Sakoulas; John Segreti; Jing J Zhao; Michael J Rybak
High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
Pharmacotherapy 2011;31(6):527-36.
2011: Ravina Kullar; Steven N Leonard; Jason M Pogue; Susan Leroque Davis; George Delgado; Bonnie Falcione; Krista A Wahby; Michael J Rybak
Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.
Pharmacotherapy 2011;31(5):441-8.
2011: Céline Vidaillac; Molly E Steed; Michael J Rybak
Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.
Antimicrobial agents and chemotherapy 2011;55(5):2160-5.
2011: Ravina Kullar; Susan Leroque Davis; Donald P Levine; Michael J Rybak
Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;52(8):975-81.
2010: Céline Vidaillac; Jeffrey R Aeschlimann; Michael J Rybak
A new assay to determine oritavancin concentrations.
The Journal of antibiotics 2010;63(12):717-9.
2010: Molly E Steed; Céline Vidaillac; Michael J Rybak
Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2010;54(12):5187-92.
2010: Jorge Parra Ruiz; Céline Vidaillac; Warren E Rose; Michael J Rybak
Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
Antimicrobial agents and chemotherapy 2010;54(10):4329-34.
2010: Kimberly D Leuthner; Céline Vidaillac; Chrissy M Cheung; Michael J Rybak
In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
Antimicrobial agents and chemotherapy 2010;54(9):3799-803.
2010: Céline Vidaillac; Steve N Leonard; Michael J Rybak
In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
International journal of antimicrobial agents 2010;35(6):527-30.
2010: Molly E Steed; Michael J Rybak
Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.
Pharmacotherapy 2010;30(4):375-89.
2010: Victor Huang; Chrissy M Cheung; Glenn W Kaatz; Michael J Rybak
Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus.
International journal of antimicrobial agents 2010;35(1):25-9.
2009: Olga V Barykina; Kerri L Rossi; Michael J Rybak; Barry B Snider
Synthesis and antibacterial properties of (-)-nor-platencin.
Organic letters 2009;11(22):5334-7.
2009: Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; William A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
Pharmacotherapy 2009;29(11):1275-9.
2009: In-Gyu Bae; Jerome J Federspiel; José M Miró; Christopher W Woods; Lawrence Park; Michael J Rybak; Thomas H Rude; Suzanne F Bradley; Suzana Bukovski; Cristina Garcia de la Maria; Souha S Kanj; Tony M Korman; Francesc Marco; David R Murdoch; Patrick Plesiat; Marta Rodriguez-Creixems; Porl Reinbott; Lisa Steed; Pierre Tattevin; Marie-Françoise Tripodi; Karly L Newton; G Ralph Corey; Vance G Fowler
Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.
The Journal of infectious diseases 2009;200(9):1355-66.
2009: Helio S Sader; Ronald N Jones; Kerri L Rossi; Michael J Rybak
Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
The Journal of antimicrobial chemotherapy 2009;64(5):1024-8.
2009: Céline Vidaillac; Steve N Leonard; Michael J Rybak
In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
Antimicrobial agents and chemotherapy 2009;53(11):4712-7.
2009: Helio S Sader; Paul D Fey; Ajit P Limaye; Nancy Madinger; Douglas N Fish; George Pankey; James Rahal; Michael J Rybak; David R Snydman; Lisa L Steed; Ken Waites; Ronald N Jones
Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006.
Antimicrobial agents and chemotherapy 2009;53(10):4127-32.
2009: Sunil K Vooturi; Chrissy M Cheung; Michael J Rybak; Steven M Firestine
Design, synthesis, and structure-activity relationships of benzophenone-based tetraamides as novel antibacterial agents.
Journal of medicinal chemistry 2009;52(16):5020-31.
2009: Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; Willam A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(3):325-7.
2009: Steven N Leonard; Céline Vidaillac; Michael J Rybak
Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2009;53(7):2928-33.
2009: Céline Vidaillac; Steve N Leonard; Helio S Sader; Ronald N Jones; Michael J Rybak
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 2009;53(6):2360-6.
2009: George Sakoulas; Pamela A Moise; Michael J Rybak
Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings?
The Journal of infectious diseases 2009;199(10):1558-9.
2009: Céline Vidaillac; Michael J Rybak
Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Pharmacotherapy 2009;29(5):511-25.
2009: Erika J Ernst; Michael E Klepser; John A Bosso; Michael J Rybak; Elizabeth D Hermsen; Marisel Segarra-Newnham; Richard H Drew
Recommendations for training and certification for pharmacists practicing, mentoring, and educating in infectious diseases pharmacotherapy.
Pharmacotherapy 2009;29(4):482-8.
2009: Steven N Leonard; Kerri L Rossi; Karly L Newton; Michael J Rybak
Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.
The Journal of antimicrobial chemotherapy 2009;63(3):489-92.
2009: Warren E Rose; Steven N Leonard; Kerri L Rossi; Glenn W Kaatz; Michael J Rybak
Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy 2009;53(2):805-7.
2009: Michael J Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2009;66(1):82-98.
2009: Steven N Leonard; Michael J Rybak
Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
The Journal of antimicrobial chemotherapy 2009;63(1):155-60.
2008: Steven N Leonard; Glenn W Kaatz; Latoyia R Rucker; Michael J Rybak
Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus.
The Journal of antimicrobial chemotherapy 2008;62(6):1305-10.
2008: Xin-Zhong Lai; Yanshu Feng; Jacob Pollard; Judy N Chin; Michael J Rybak; Robert Bucki; Raquel F Epand; Richard M Epand; Paul B Savage
Ceragenins: cholic acid-based mimics of antimicrobial peptides.
Accounts of chemical research 2008;41(10):1233-40.
2008: Michael J Rybak; Steve N Leonard; Kerri L Rossi; Chrissy M Cheung; Helio S Sader; Helio S Sadar; Ronald Jones
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).
Journal of clinical microbiology 2008;46(9):2950-4.
2008: Tahaniyat Lalani; Jerome J Federspiel; Helen W Boucher; Thomas H Rude; In-Gyu Bae; Michael J Rybak; Giang T Tonthat; G Ralph Corey; Martin E Stryjewski; George Sakoulas; Vivian H Chu; Jeff Alder; Judith N Steenbergen; Steven A Luperchio; Marilyn Campion; Christopher W Woods; Vance G Fowler
Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients.
Journal of clinical microbiology 2008;46(9):2890-6.
2008: Warren E Rose; Steven N Leonard; Michael J Rybak
Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2008;52(9):3061-7.
2008: Steven N Leonard; Chrissy M Cheung; Michael J Rybak
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2008;52(8):2974-6.
2008: Zukile Gqada; Ben Marais; Elizabeth Wasserman; Colleen Bamford; Heidi Orth; George Sakoulas; Warren E Rose; Michael J Rybak; Satish Pillai; Jeff Alder; Robert C Moellering; George Miltiades Eliopoulos
Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.
Journal of clinical microbiology 2008;46(7):2471; author reply 2471-2.
2008: Kerry L LaPlante; Steven N Leonard; David R Andes; William A Craig; Michael J Rybak
Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.
Antimicrobial agents and chemotherapy 2008;52(6):2156-62.
2008: Warren E Rose; Glenn W Kaatz; George Sakoulas; Michael J Rybak
Teicoplanin pharmacodynamics in reference to the accessory gene regulator (agr) in Staphylococcus aureus using an in vitro pharmacodynamic model.
The Journal of antimicrobial chemotherapy 2008;61(5):1099-102.
2008: Steven N Leonard; Michael J Rybak
Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
Pharmacotherapy 2008;28(4):458-68.
2008: Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; Michael J Rybak
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus.
Journal of medical microbiology 2008;57(Pt 4):452-6.
2008: Brian T Tsuji; Steven N Leonard; Paul R Rhomberg; Ronald Jones; Michael J Rybak
Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum.
Diagnostic microbiology and infectious disease 2008;60(4):441-4.
2008: Warren E Rose; Steven N Leonard; George Sakoulas; Glenn W Kaatz; Marcus Zervos; Anjly Sheth; Christopher F Carpenter; Michael J Rybak
daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2008;52(3):831-6.
2008: Judy N Chin; Ronald Jones; Helio S Sader; Paul B Savage; Michael J Rybak
Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
The Journal of antimicrobial chemotherapy 2008;61(2):365-70.
2008: George Sakoulas; Warren E Rose; Michael J Rybak; Satish Pillai; Jeff Alder; Robert C Moellering; George Miltiades Eliopoulos
Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.
Journal of clinical microbiology 2008;46(1):220-4.
2007: Susan Leroque Davis; Peggy S McKinnon; Levi M Hall; George Delgado; Warren E Rose; Robert F Wilson; Michael J Rybak
Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Pharmacotherapy 2007;27(12):1611-8.
2007: Dennis G Maki; Steven C Ebert; Michael J Rybak
Case study and panel discussion.
Pharmacotherapy 2007;27(10 Pt 2):136S-143S.
2007: Michael J Rybak
Antimicrobial stewardship.
Pharmacotherapy 2007;27(10 Pt 2):131S-135S.
2007: Thomas P Lodise; Peggy S McKinnon; Donald P Levine; Michael J Rybak
Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2007;51(10):3731-3.
2007: Warren E Rose; Michael J Rybak; Glenn W Kaatz
Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
The Journal of antimicrobial chemotherapy 2007;60(2):334-40.
2007: Warren E Rose; Michael J Rybak; Brian T Tsuji; Glenn W Kaatz; George Sakoulas
Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.
The Journal of antimicrobial chemotherapy 2007;59(6):1190-3.
2007: Brian T Tsuji; Michael J Rybak; Chrissy M Cheung; Muhammad Amjad; Glenn W Kaatz
Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents.
Diagnostic microbiology and infectious disease 2007;58(1):41-7.
2007: Kerry L LaPlante; Michael J Rybak; Brian T Tsuji; Thomas P Lodise; Glenn W Kaatz
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Antimicrobial agents and chemotherapy 2007;51(4):1315-20.
2007: Judy N Chin; Michael J Rybak; Chrissy M Cheung; Paul B Savage
Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2007;51(4):1268-73.
2007: Brian T Tsuji; Michael J Rybak; Kerry L Lau; George Sakoulas
Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2007;51(3):1089-91.
2007: Kerry L LaPlante; Michael J Rybak; Muhammad Amjad; Glenn W Kaatz
Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus.
Pharmacotherapy 2007;27(1):3-10.
2006: Susan Leroque Davis; Michael J Rybak; Muhammad Amjad; Glenn W Kaatz; Peggy S McKinnon
Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2006;27(10):1025-31.
2006: Warren E Rose; Michael J Rybak
Tigecycline: first of a new class of antimicrobial agents.
Pharmacotherapy 2006;26(8):1099-110.
2006: Kimberly D Leuthner; Chrissy M Cheung; Michael J Rybak
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
The Journal of antimicrobial chemotherapy 2006;58(2):338-43.
2006: Michael J Rybak
Pharmacodynamics: relation to antimicrobial resistance.
American journal of infection control 2006;34(5 Suppl 1):S38-45; discussion S64-73.
2006: Michael J Rybak
Pharmacodynamics: relation to antimicrobial resistance.
The American journal of medicine 2006;119(6 Suppl 1):S37-44; discussion S62-70.
2006: Kerry L LaPlante; Michael J Rybak; Kimberly D Leuthner; Judy N Chin
Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
Antimicrobial agents and chemotherapy 2006;50(4):1298-303.
2006: Robert J Kerns; Michael J Rybak; Chrissy M Cheung
Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria.
Diagnostic microbiology and infectious disease 2006;54(4):305-10.
2006: Michael J Rybak
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12 Suppl 1():24-32.
2006: Kimberly D Leuthner; Chrissy M Cheung; Michael J Rybak
Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2006;50(2):813-6.
2006: Brian T Tsuji; Michael J Rybak
Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin.
Diagnostic microbiology and infectious disease 2006;54(1):73-7.
2006: Michael J Rybak
The pharmacokinetic and pharmacodynamic properties of vancomycin.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42 Suppl 1():S35-9.
2006: Victor Huang; Michael J Rybak
Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.
The Journal of antimicrobial chemotherapy 2006;57(1):116-21.
2005: C Andrew DeRyke; Thomas P Lodise; Michael J Rybak; Peggy S McKinnon
Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia.
Chest 2005;128(3):1414-22.
2005: Brian T Tsuji; Michael J Rybak
Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2005;49(7):2735-45.
2005: Michael J Rybak; Raymond Cha; Chrissy M Cheung; Venkata G Meka; Glenn W Kaatz
Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin.
Diagnostic microbiology and infectious disease 2005;51(2):119-25.
2005: Michael J Rybak; Kerry L LaPlante
Community-associated methicillin-resistant Staphylococcus aureus: a review.
Pharmacotherapy 2005;25(1):74-85.
2005: Victor Huang; Michael J Rybak
Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Antimicrobial agents and chemotherapy 2005;49(1):302-8.
2004: Michael J Rybak
Resistance to antimicrobial agents: an update.
Pharmacotherapy 2004;24(12 Pt 2):203S-15S.
2004: Kerry L LaPlante; Michael J Rybak
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy 2004;48(12):4665-72.
2004: Raymond Cha; Michael J Rybak
Pulsatile delivery of amoxicillin against Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 2004;54(6):1067-71.
2004: Kerry L LaPlante; Michael J Rybak
Daptomycin - a novel antibiotic against Gram-positive pathogens.
Expert opinion on pharmacotherapy 2004;5(11):2321-31.
2004: Robert W Finberg; Robert C Moellering; Francis P Tally; William A Craig; George A Pankey; E Patchen Dellinger; Michael A West; Manjari Joshi; Peter K Linden; Ken V Rolston; John C Rotschafer; Michael J Rybak
The importance of bactericidal drugs: future directions in infectious disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(9):1314-20.
2004: Kerry L LaPlante; Michael J Rybak
Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline.
Diagnostic microbiology and infectious disease 2004;50(2):125-30.
2004: Michael J Rybak
Increased bacterial resistance: PROTEKT US--an update.
The Annals of pharmacotherapy 2004;38(9 Suppl):S8-S13.
2004: George P Allen; Glenn W Kaatz; Michael J Rybak
In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
International journal of antimicrobial agents 2004;24(2):150-60.
2004: Steven D Brown; Michael J Rybak
Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
The Journal of antimicrobial chemotherapy 2004;54 Suppl 1():i7-15.
2004: Victor Huang; William J Brown; Michael J Rybak
In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
Antimicrobial agents and chemotherapy 2004;48(7):2719-23.
2004: Raymond Cha; Michael J Rybak
Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model.
The Journal of antimicrobial chemotherapy 2004;54(1):259-62.
2004: Kerry L Tedesco; Michael J Rybak
Daptomycin.
Pharmacotherapy 2004;24(1):41-57.
2003: Raymond Cha; Ronda L Akins; Michael J Rybak
Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Pharmacotherapy 2003;23(12):1531-7.
2003: Raymond Cha; William J Brown; Michael J Rybak
Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2003;47(12):3960-3.
2003: Raymond Cha; Michael J Rybak
Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Diagnostic microbiology and infectious disease 2003;47(3):539-46.
2003: Thomas P Lodise; Peggy S McKinnon; Michael J Rybak
Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2003;24(9):655-61.
2003: George P Allen; Glenn W Kaatz; Michael J Rybak
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy 2003;47(8):2606-14.
2003: Robert J Kerns; Michael J Rybak; Glenn W Kaatz; Flamur Vaka; Raymond Cha; Richard G Grucz; Veena U Diwadkar
Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus.
Bioorganic & medicinal chemistry letters 2003;13(13):2109-12.
2003: Thomas P Lodise; Peggy S McKinnon; Linda Swiderski; Michael J Rybak
Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(11):1418-23.
2003: Raymond Cha; Michael J Rybak
Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy 2003;47(6):1984-7.
2003: Vincent H Tam; Peggy S McKinnon; Ronda L Akins; George L Drusano; Michael J Rybak
Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.
Antimicrobial agents and chemotherapy 2003;47(6):1853-61.
2003: Robert J Kerns; Michael J Rybak; Glenn W Kaatz; Flamur Vaka; Raymond Cha; Richard G Grucz; Veena U Diwadkar; Tracey D Ward
Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus.
Bioorganic & medicinal chemistry letters 2003;13(10):1745-9.
2003: Roger L White; Charles R Bonapace; Lawrence V Friedrich; Michael J Rybak; DM Cappelletty; Renee-Claude Mercier; Heather H Houlihan; Jeffrey R Aeschlimann; John A Bosso
Assessment of differences in antimicrobial effect determined with two in vitro pharmacodynamic models: impact of surface area to volume ratio.
Pharmacotherapy 2003;23(5):603-8.
2003: Elizabeth A Coyle; Raymond Cha; Michael J Rybak
Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release.
Antimicrobial agents and chemotherapy 2003;47(5):1752-5.
2003: Raymond Cha; Richard G Grucz; Michael J Rybak
Daptomycin dose-effect relationship against resistant gram-positive organisms.
Antimicrobial agents and chemotherapy 2003;47(5):1598-603.
2003: Jim Zhiming Li; Richard J Willke; Brian E Rittenhouse; Michael J Rybak
Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
Surgical infections 2003;4(1):57-70.
2002: Vincent H Tam; Peggy S McKinnon; Ronda L Akins; Michael J Rybak; George L Drusano
Pharmacodynamics of cefepime in patients with Gram-negative infections.
The Journal of antimicrobial chemotherapy 2002;50(3):425-8.
2002: George P Allen; Raymond Cha; Michael J Rybak
In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy 2002;46(8):2606-12.
2002: Renee-Claude Mercier; Carmine Stumpo; Michael J Rybak
Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
The Journal of antimicrobial chemotherapy 2002;50(1):19-24.
2002: Thomas P Lodise; Peggy S McKinnon; Vincent H Tam; Michael J Rybak
Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(7):922-9.
2001: Michael J Rybak
Therapeutic options for Gram-positive infections.
The Journal of hospital infection 2001;49 Suppl A():S25-32.
2001: Andrea L H Kwa; Vincent H Tam; Michael J Rybak
Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review.
Pharmacotherapy 2001;21(8):998-1002.
2001: EA Coyle; Glenn W Kaatz; Michael J Rybak
Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2001;45(6):1654-9.
2001: Glenn W Kaatz; Michael J Rybak
Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria.
Expert opinion on emerging drugs 2001;6(1):43-55.
2001: Z Li; Richard J Willke; L A Pinto; Brian E Rittenhouse; Michael J Rybak; A M Pleil; C W Crouch; Barry Hafkin; Henry A Glick
Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial.
Pharmacotherapy 2001;21(3):263-74.
2001: EA Coyle; Michael J Rybak
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy 2001;45(3):706-9.
2001: T K Jellison; Peggy S McKinnon; Michael J Rybak
Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.
Pharmacotherapy 2001;21(2):142-8.
2001: Ronda L Akins; Michael J Rybak
Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2001;45(2):454-9.
2001: Michael J Rybak; Ronda L Akins
Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options.
Drugs 2001;61(1):1-7.
2000: Jeffrey R Aeschlimann; George P Allen; Ellie Hershberger; Michael J Rybak
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Antimicrobial agents and chemotherapy 2000;44(11):2991-8.
2000: Vincent H Tam; Peggy S McKinnon; Donald P Levine; S M Brandel; Michael J Rybak
Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review.
Pharmacotherapy 2000;20(9):1116-9.
2000: Renee-Claude Mercier; Michael J Rybak; A S Bayer; Michael Yeaman
Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis.
Infection and immunity 2000;68(8):4699-705.
2000: Heather H Houlihan; D P Stokes; Michael J Rybak
Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model.
The Journal of antimicrobial chemotherapy 2000;46(1):79-86.
2000: Ronda L Akins; Michael J Rybak
In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.
Antimicrobial agents and chemotherapy 2000;44(7):1925-9.
2000: Ellie Hershberger; EA Coyle; Glenn W Kaatz; Marcus Zervos; Michael J Rybak
Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 2000;44(7):1921-4.
2000: MM Neuhauser; Peggy S McKinnon; Ellie Hershberger; Michael J Rybak
Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function.
Pharmacotherapy 2000;20(5):554-61.
2000: Jeffrey R Aeschlimann; Ellie Hershberger; Michael J Rybak
Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Antimicrobial agents and chemotherapy 2000;44(5):1153-8.
2000: Michael J Rybak; Ellie Hershberger; T Moldovan; Richard G Grucz
In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
Antimicrobial agents and chemotherapy 2000;44(4):1062-6.
2000: Ellie Hershberger; Michael J Rybak
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Antimicrobial agents and chemotherapy 2000;44(3):598-601.
1999: Kellie R Murry; Peggy S McKinnon; B Mitrzyk; Michael J Rybak
Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside.
Pharmacotherapy 1999;19(11):1252-60.
1999: D R Foster; Michael J Rybak
Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin family.
Pharmacotherapy 1999;19(10):1111-7.
1999: CM Weingarten; Michael J Rybak; Brian Jahns; J G Stevenson; William J Brown; Donald P Levine
Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital.
Pharmacotherapy 1999;19(9):1080-5.
1999: Jeffrey R Aeschlimann; Glenn W Kaatz; Michael J Rybak
The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.
The Journal of antimicrobial chemotherapy 1999;44(3):343-9.
1999: Jeffrey R Aeschlimann; Ellie Hershberger; Michael J Rybak
Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus.
Antimicrobial agents and chemotherapy 1999;43(8):1914-8.
1999: Michael J Rybak; B J Abate; S L Kang; M J Ruffing; Stephen A Lerner; George L Drusano
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
Antimicrobial agents and chemotherapy 1999;43(7):1549-55.
1999: C M Karam; Peggy S McKinnon; MM Neuhauser; Michael J Rybak
Outcome assessment of minimizing vancomycin monitoring and dosing adjustments.
Pharmacotherapy 1999;19(3):257-66.
1999: Ellie Hershberger; Jeffrey R Aeschlimann; T Moldovan; Michael J Rybak
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
Antimicrobial agents and chemotherapy 1999;43(3):717-21.
1999: Jeffrey R Aeschlimann; L D Dresser; Glenn W Kaatz; Michael J Rybak
Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus.
Antimicrobial agents and chemotherapy 1999;43(2):335-40.
1998: Jeffrey R Aeschlimann; Marcus Zervos; Michael J Rybak
Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
Antimicrobial agents and chemotherapy 1998;42(10):2710-7.
1998: Jeffrey R Aeschlimann; Michael J Rybak
Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.
Antimicrobial agents and chemotherapy 1998;42(9):2188-92.
1998: J A Rebuck; Michael J Rybak; D P Ramos; CM Weingarten
Omeprazole-induced exfoliative dermatitis.
Pharmacotherapy 1998;18(4):877-9.
1998: K Shimada; A Saito; K Yamaguchi; T Inamatsu; Y Kobayashi; T Oguma; Glenn W Kaatz; Michael J Rybak; John M Boyce; M L Zeckel; H Murao
[The 3rd Japanese-United States Vancomycin Forum].
The Japanese journal of antibiotics 1998;51(6):363-94.
1998: L D Dresser; Michael J Rybak
The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials.
Pharmacotherapy 1998;18(3):456-62.
1998: Glenn W Kaatz; Susan M Seo; Jeffrey R Aeschlimann; Heather H Houlihan; Renee-Claude Mercier; Michael J Rybak
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
Antimicrobial agents and chemotherapy 1998;42(4):981-3.
1998: Michael J Rybak; DM Cappelletty; T Moldovan; Jeffrey R Aeschlimann; Glenn W Kaatz
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
Antimicrobial agents and chemotherapy 1998;42(3):721-4.
1998: Glenn W Kaatz; Susan M Seo; Jeffrey R Aeschlimann; Heather H Houlihan; Renee-Claude Mercier; Michael J Rybak
Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.
Antimicrobial agents and chemotherapy 1998;42(2):254-6.
1998: R S Slavik; Michael J Rybak; Stephen A Lerner
Trimethoprim/sulfamethoxazole-induced tremor in a patient with AIDS.
The Annals of pharmacotherapy 1998;32(2):189-92.
1997: Renee-Claude Mercier; S R Penzak; Michael J Rybak
In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.
Antimicrobial agents and chemotherapy 1997;41(11):2573-5.
1997: Heather H Houlihan; Renee-Claude Mercier; Michael J Rybak
Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
Antimicrobial agents and chemotherapy 1997;41(11):2497-501.
1997: Michael J Rybak; Heather H Houlihan; Renee-Claude Mercier; Glenn W Kaatz
Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
Antimicrobial agents and chemotherapy 1997;41(6):1359-63.
1997: Renee-Claude Mercier; Heather H Houlihan; Michael J Rybak
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Antimicrobial agents and chemotherapy 1997;41(6):1307-12.
1997: S L Kang; Michael J Rybak
In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
The Journal of antimicrobial chemotherapy 1997;39 Suppl A():33-9.
1997: S M Palmer; Michael J Rybak
An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots.
The Journal of antimicrobial chemotherapy 1997;39(4):515-8.
1997: K G Przybylski; Michael J Rybak; P R Martin; CM Weingarten; F K Zaran; J G Stevenson; Donald P Levine
A pharmacist-initiated program of intravenous to oral antibiotic conversion.
Pharmacotherapy 1997;17(2):271-6.
1996: B Mitrzyk; P E Jarco; Michael J Rybak
Stability and antimicrobial activity of gentamicin sulfate, tobramycin sulfate and amikacin sulfate in polypropylene syringes for use in once-daily aminoglycoside therapy.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1996;53(23):2855-9.
1996: F K Zaran; CM Weingarten; Michael J Rybak; J G Stevenson
Effect of constructive feedback on pharmacist handling of orders for monitored antimicrobials.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1996;53(18):2196-8.
1996: S M Palmer; Michael J Rybak
Vancomycin-resistant enterococci.
Pharmacotherapy 1996;16(5):819-29.
1996: Michael J Rybak; B J McGrath
Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician.
Drugs 1996;52(3):390-405.
1996: Michael J Rybak
The pharmacokinetic profile of a new generation of parenteral cephalosporin.
The American journal of medicine 1996;100(6A):39S-44S.
1996: DM Cappelletty; Michael J Rybak
Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
Antimicrobial agents and chemotherapy 1996;40(5):1148-52.
1996: S M Palmer; Michael J Rybak
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.
Antimicrobial agents and chemotherapy 1996;40(3):701-5.
1996: J K James; S M Palmer; Donald P Levine; Michael J Rybak
Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
Antimicrobial agents and chemotherapy 1996;40(3):696-700.
1996: A S Benko; DM Cappelletty; James A Kruse; Michael J Rybak
Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
Antimicrobial agents and chemotherapy 1996;40(3):691-5.
1996: DM Cappelletty; Michael J Rybak
Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1996;40(3):677-83.
1996: K C Lamp; Michael J Rybak; B J McGrath; K K Summers
Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1996;40(1):247-52.
1995: S L Kang; Michael J Rybak
Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots.
Antimicrobial agents and chemotherapy 1995;39(12):2832-4.
1995: C Chant; Michael J Rybak
Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic.
The Annals of pharmacotherapy 1995;29(10):1022-7.
1995: Michael J Rybak; S M Palmer
Vancomycin-resistant enterococci.
Pharmacotherapy 1995;15(5):684-5.
1995: DM Cappelletty; S L Kang; S M Palmer; Michael J Rybak
Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Antimicrobial agents and chemotherapy 1995;39(8):1797-801.
1995: S M Palmer; S L Kang; DM Cappelletty; Michael J Rybak
Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model.
Antimicrobial agents and chemotherapy 1995;39(8):1764-71.
1995: S L Kang; Michael J Rybak
Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.
Antimicrobial agents and chemotherapy 1995;39(7):1505-11.
1994: S L Kang; Michael J Rybak; B J McGrath; Glenn W Kaatz; Susan M Seo
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
Antimicrobial agents and chemotherapy 1994;38(12):2702-9.
1994: B J McGrath; S L Kang; Glenn W Kaatz; Michael J Rybak
Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.
Antimicrobial agents and chemotherapy 1994;38(9):2034-40.
1994: J C Rotschafer; Michael J Rybak
Single daily dosing of aminoglycosides: a commentary.
The Annals of pharmacotherapy 1994;28(6):797-801.
1994: K A Loughlin; C M Bakst; Michael J Rybak
Oral treatment of gonorrhea and chlamydia.
The Annals of pharmacotherapy 1994;28(5):600-2.
1994: Michael J Rybak; S M Palmer
Cefepime: part of the new generation.
American journal of hospital pharmacy 1994;51(4):459-60.
1994: D Stanley; B J McGrath; K C Lamp; Michael J Rybak
Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus.
Pharmacotherapy 1994;14(1):35-9.
1993: S A Tailor; E M Bailey; Michael J Rybak
Enterococcus, an emerging pathogen.
The Annals of pharmacotherapy 1993;27(10):1231-42.
1993: T L O'Sullivan; M J Ruffing; K C Lamp; L H Warbasse; Michael J Rybak
Prospective evaluation of red man syndrome in patients receiving vancomycin.
The Journal of infectious diseases 1993;168(3):773-6.
1993: B J McGrath; K C Lamp; Michael J Rybak
Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
Antimicrobial agents and chemotherapy 1993;37(9):1931-7.
1993: K C Lamp; Michael J Rybak
Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium.
Antimicrobial agents and chemotherapy 1993;37(3):605-9.
1993: Michael J Rybak; R Allen; P Arnow; P C Craven; R Freeman; R N Grüneberg; J Korin; C H Nightingale; E Rubinstein; G S Schaison
Roundtable discussion. Maximizing potential cost benefits of teicoplanin through appropriate usage.
Hospital formulary 1993;28 Suppl 1():62-8.
1993: Michael J Rybak; R Allen; P C Craven; R Freeman; C H Nightingale; C Normand; E Rubinstein; G S Schaison; G Whitelaw
Roundtable discussion. Cost justification of innovative drugs through assessment of total health care costs.
Hospital formulary 1993;28 Suppl 1():33-6.
1993: Michael J Rybak
Teicoplanin vs vancomycin: cost-effectiveness comparisons.
Hospital formulary 1993;28 Suppl 1():28-32.
1992: B J McGrath; E M Bailey; K C Lamp; Michael J Rybak
Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
Antimicrobial agents and chemotherapy 1992;36(12):2741-6.
1992: K C Lamp; Michael J Rybak; E M Bailey; Glenn W Kaatz
In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.
Antimicrobial agents and chemotherapy 1992;36(12):2709-14.
1992: J G Stevenson; C M Bakst; F K Zaran; Michael J Rybak; R T Smolarek; M R Alexander
Quality improvement in the use of medications through a drug use evaluation service.
Topics in hospital pharmacy management / Aspen Systems Corporation 1992;12(3):47-56.
1992: J R Berman; F K Zaran; Michael J Rybak
Pharmacy-based antimicrobial-monitoring service.
American journal of hospital pharmacy 1992;49(7):1701-6.
1992: Michael J Rybak; E M Bailey; L H Warbasse
Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin.
Antimicrobial agents and chemotherapy 1992;36(6):1204-7.
1992: Glenn W Kaatz; Susan M Seo; K C Lamp; E M Bailey; Michael J Rybak
CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
Antimicrobial agents and chemotherapy 1992;36(6):1192-7.
1992: Michael J Rybak; E M Bailey; K C Lamp; Glenn W Kaatz
Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.
Antimicrobial agents and chemotherapy 1992;36(5):1109-14.
1992: K C Lamp; E M Bailey; Michael J Rybak
Ofloxacin clinical pharmacokinetics.
Clinical pharmacokinetics 1992;22(1):32-46.
1992: W R Melchior; V Bindlish; Michael J Rybak
Intravitreal ganciclovir for cytomegalovirus retinitis in AIDS patients.
The Annals of pharmacotherapy 1992;26(1):36-7.
1991: Glenn W Kaatz; Susan M Seo; S L Barriere; L M Albrecht; Michael J Rybak
Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.
Antimicrobial agents and chemotherapy 1991;35(8):1547-50.
1991: Michael J Rybak; E M Bailey; V N Reddy
Clinical evaluation of teicoplanin fluorescence polarization immunoassay.
Antimicrobial agents and chemotherapy 1991;35(8):1586-90.
1991: L M Albrecht; Michael J Rybak; L H Warbasse; David J Edwards
Vancomycin protein binding in patients with infections caused by Staphylococcus aureus.
DICP : the annals of pharmacotherapy 1991;25(7-8):713-5.
1991: E M Bailey; Michael J Rybak; Glenn W Kaatz
Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.
Antimicrobial agents and chemotherapy 1991;35(6):1089-92.
1991: Michael J Rybak; Stephen A Lerner; Donald P Levine; L M Albrecht; Paul L McNeil; G A Thompson; M T Kenny; L Yuh
Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis.
Antimicrobial agents and chemotherapy 1991;35(4):696-700.
1991: N M Waite; Michael J Rybak; D J Krakovsky; Joel David Steinberg; L H Warbasse; David J Edwards
Influence of subject age on the inhibition of oxidative metabolism by ciprofloxacin.
Antimicrobial agents and chemotherapy 1991;35(1):130-4.
1990: Glenn W Kaatz; Susan M Seo; V N Reddy; E M Bailey; Michael J Rybak
Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.
Antimicrobial agents and chemotherapy 1990;34(11):2081-5.
1990: E M Bailey; T D Constance; L M Albrecht; Michael J Rybak
Coagulase-negative staphylococci: incidence, pathogenicity, and treatment in the 1990s.
DICP : the annals of pharmacotherapy 1990;24(7-8):714-20.
1990: Michael J Rybak; L M Albrecht; J R Berman; L H Warbasse; Craig K Svensson
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.
Antimicrobial agents and chemotherapy 1990;34(5):792-5.
1990: N J Leggett; C Caravaggio; Michael J Rybak
Cefixime.
DICP : the annals of pharmacotherapy 1990;24(5):489-95.
1990: Michael J Rybak; L M Albrecht; S C Boike; Pranatharthi H Chandrasekar
Nephrotoxicity of vancomycin, alone and with an aminoglycoside.
The Journal of antimicrobial chemotherapy 1990;25(4):679-87.
1990: Glenn W Kaatz; Susan M Seo; S L Barriere; L M Albrecht; Michael J Rybak
Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.
Antimicrobial agents and chemotherapy 1990;34(2):257-60.
1990: E M Bailey; D J Krakovsky; Michael J Rybak
The triazole antifungal agents: a review of itraconazole and fluconazole.
Pharmacotherapy 1990;10(2):146-53.
1989: Maureen A Smythe; Michael J Rybak
Ofloxacin: a review.
DICP : the annals of pharmacotherapy 1989;23(11):839-46.
1989: Glenn W Kaatz; Susan M Seo; S L Barriere; L M Albrecht; Michael J Rybak
Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.
Antimicrobial agents and chemotherapy 1989;33(8):1184-7.
1989: L M Albrecht; Michael J Rybak; Howard Schubiner; L M Weiner
Single dose enoxacin for the treatment of uncomplicated urogenital gonorrhea.
Sexually transmitted diseases 1989;16(2):114-7.
1989: Glenn W Kaatz; Susan M Seo; S L Barriere; L M Albrecht; Michael J Rybak
Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
Antimicrobial agents and chemotherapy 1989;33(4):519-21.
1989: Linda A Jaber; E M Bailey; Michael J Rybak
Enoxacin: a new fluoroquinolone.
Clinical pharmacy 1989;8(2):97-107.
1988: David J Edwards; S K Bowles; Craig K Svensson; Michael J Rybak
Inhibition of drug metabolism by quinolone antibiotics.
Clinical pharmacokinetics 1988;15(3):194-204.
1988: Pranatharthi H Chandrasekar; Donald P Levine; S Price; Michael J Rybak
Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus.
The Journal of antimicrobial chemotherapy 1988;21(4):461-9.
1988: S K Bowles; Z Popovski; Michael J Rybak; Howard Beckman; David J Edwards
Effect of norfloxacin on theophylline pharmacokinetics at steady state.
Antimicrobial agents and chemotherapy 1988;32(4):510-2.
1988: L M Albrecht; Michael J Rybak; S C Boike; S Pancorbo
Comparison of serum sampling methods for determining vancomycin dosage regimens.
Therapeutic drug monitoring 1988;10(1):85-90.
1987: Michael J Rybak; S K Bowles; Pranatharthi H Chandrasekar; David J Edwards
Increased theophylline concentrations secondary to ciprofloxacin.
Drug intelligence & clinical pharmacy 1987;21(11):879-81.
1987: Michael J Rybak; J J Frankowski; David J Edwards; L M Albrecht
Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicin.
Antimicrobial agents and chemotherapy 1987;31(10):1461-4.
1987: D K Terp; Michael J Rybak
Ciprofloxacin.
Drug intelligence & clinical pharmacy 1987;21(7-8):568-74.
1987: A M Pilla; Michael J Rybak; Pranatharthi H Chandrasekar
Spiramycin in the treatment of cryptosporidiosis.
Pharmacotherapy 1987;7(5):188-90.
1986: Pranatharthi H Chandrasekar; Michael J Rybak; J J Frankowski
White blood cell count and vancomycin.
The American journal of medicine 1986;81(6):1114.
1986: L M Babiak; Michael J Rybak
Hematological effects associated with beta-lactam use.
Drug intelligence & clinical pharmacy 1986;20(11):833-6.
1986: Z Popovski; Michael J Rybak
Potential theophylline toxicity with enoxacin.
Drug intelligence & clinical pharmacy 1986;20(11):889-90.
1986: Michael J Rybak; S C Boike
Monitoring vancomycin therapy.
Drug intelligence & clinical pharmacy 1986;20(10):757-61.
1986: L M Albrecht; Michael J Rybak
Combination imipenem-aminoglycoside therapy.
Drug intelligence & clinical pharmacy 1986;20(6):506.
1986: V Tutag-Lehr; Michael J Rybak
Aminoglycoside pharmacokinetics in patients with spinal cord injury.
Clinical pharmacy 1986;5(2):109, 112.
1986: Michael J Rybak; S C Boike; Donald P Levine; S R Erickson
Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis.
The Journal of antimicrobial chemotherapy 1986;17(1):115-20.
1986: N Saad; Michael J Rybak
Transdermal clonidine.
Drug intelligence & clinical pharmacy 1986;20(1):78.
1986: Michael J Rybak; S C Boike
Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms.
Drug intelligence & clinical pharmacy 1986;20(1):64-8.
1985: G R Matzke; J M Kovarik; Michael J Rybak; S C Boike
Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage.
Clinical pharmacy 1985;4(3):311-5.
1985: D S Bach; Michael J Rybak
Haloperidol-associated hyperthermia.
Drug intelligence & clinical pharmacy 1985;19(3):211.
1984: L M Gutschi; Michael J Rybak
Antihypertensive agents and hyperlipidemia.
Clinical pharmacy 1984;3(6):587-8.
1984: S R Erickson; S A Hunt; Michael J Rybak
Sensitivity testing and the inoculum effect.
Drug intelligence & clinical pharmacy 1984;18(6):530.
1984: G Dunn; Michael J Rybak
Nonlinear theophylline kinetics.
Drug intelligence & clinical pharmacy 1984;18(2):155.
1983: S C Boike; Michael J Rybak
Pharmacologic interventions in resuscitation.
Emergency medicine clinics of North America 1983;1(3):553-69.
1983: F Lobeck; Michael J Rybak
Proper inhaler technique.
Clinical pharmacy 1983;2(6):512.
1983: Michael J Rybak; S C Boike
Additive toxicity in patients receiving vancomycin and aminoglycosides.
Clinical pharmacy 1983;2(6):508.
1983: S C Boike; Michael J Rybak; Judith Tintinalli; D K Solomon; M F Powell; J H Trombley; C Sacks; S Freeman
Evaluation of a method for intravenous phenytoin infusion.
Clinical pharmacy 1983;2(5):444-6.
1983: S A Hunt; Michael J Rybak
Subminimum inhibitory concentrations of antimicrobials.
Drug intelligence & clinical pharmacy 1983;17(7-8):560-1.
1983: S C Boike; Michael J Rybak; Judith Tintinalli; R Veneri
Zomepirac-related acute renal failure.
Drug intelligence & clinical pharmacy 1983;17(1):56-7.
1982: S A Hunt; Michael J Rybak
Antimicrobial susceptibility tests.
Drug intelligence & clinical pharmacy 1982;16(9):703-5.
1982: Michael J Rybak; S C Boike; P W Bush
Treatment of pseudomonal endocarditis with high-dose aminoglycosides.
Drug intelligence & clinical pharmacy 1982;16(9):700-2.
1979: Michael J Rybak; R Gleckman
Incorrect or unsubstantiated indications listed for selected antimicrobials in the Physicians' Desk Reference.
American journal of hospital pharmacy 1979;36(6):738.